Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lapointe

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir sizeMaggie C Duncan, F Harrison Omondi, Natalie N Kinloch, et al.
AIDS (London, England)|January 15, 2024
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir sizeMaggie C Duncan, F Harrison Omondi, Natalie N Kinloch, et al.
Viruses|May 25, 2024
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral TherapySneha Datwani, Rebecca Kalikawe, Rachel Waterworth, et al.
Open Forum Infectious Diseases|March 13, 2023
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA VaccineFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
Journal of Medicinal Chemistry|December 31, 2008
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitorsPaul A Renhowe, Sabina Pecchi, Cynthia M Shafer, et al.
The Journal of Infectious Diseases|December 10, 2021
Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older AdultsMark A Brockman, Francis Mwimanzi, Hope R Lapointe, et al.
Frontiers in Immunology|September 23, 2022
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccinationHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Vaccines|May 25, 2024
Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 StudyCecilia T Costiniuk, Terry Lee, Joel Singer, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
AIDS (London, England)|December 8, 2022
COVID-19 vaccine immunogenicity in people with HIVCecilia T Costiniuk, Joel Singer, Terry Lee, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Medrxiv : the Preprint Server for Health Sciences|October 24, 2023
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir sizeMaggie C Duncan, F Harrison Omondi, Natalie N Kinloch, et al.
AIDS (London, England)|January 15, 2024
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir sizeMaggie C Duncan, F Harrison Omondi, Natalie N Kinloch, et al.
Viruses|May 25, 2024
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral TherapySneha Datwani, Rebecca Kalikawe, Rachel Waterworth, et al.
Open Forum Infectious Diseases|March 13, 2023
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA VaccineFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
Journal of Medicinal Chemistry|December 31, 2008
Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitorsPaul A Renhowe, Sabina Pecchi, Cynthia M Shafer, et al.
The Journal of Infectious Diseases|December 10, 2021
Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older AdultsMark A Brockman, Francis Mwimanzi, Hope R Lapointe, et al.
Frontiers in Immunology|September 23, 2022
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccinationHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Vaccines|May 25, 2024
Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 StudyCecilia T Costiniuk, Terry Lee, Joel Singer, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
AIDS (London, England)|December 8, 2022
COVID-19 vaccine immunogenicity in people with HIVCecilia T Costiniuk, Joel Singer, Terry Lee, et al.
Pageof 15